Novo Holdings leads $50 million growth financing in Route 92 Medical

Financing to support acceleration of commercial growth

SAN FRANCISCO, and WEST JORDAN, Utah— Novo Holdings today announced a $50 million growth financing in Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention. New investor Sectoral Asset Management joined Novo Holdings in the round, as well as existing investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners, and The Vertical Group.

Proceeds from the Series F-2 preferred stock financing will support the next phase of Route 92 Medical’s growth strategy by helping to further accelerate global commercial expansion, advance clinical evidence to broaden adoption of the company’s neurovascular procedural approach, and invest in continued product innovation across its platform.

Tony Chou, MD, Chief Executive Officer and Founder of Route 92 Medical, said: “We’ve seen rapid growth in the adoption of our products over the past year, attributable to the clinical performance of procedures with our Monopoint approach, and the growth and dedication of our commercial organization. We’re on a mission to improve outcomes for patients suffering from acute ischemic stroke and our rapidly growing sales are a testament to the differentiated, physician-preferred attributes of our neurovascular thrombectomy solutions.”

Noel Jee, Ph.D., Partner, Growth Investments, Novo Holdings, commented: “We believe Route 92 is setting new standards in neurovascular intervention, with Tenzing, HiPoint, and FreeClimb improving how physicians navigate complex procedures and treat ischemic stroke. Real-world experience validates the strength of these technologies, and we’re excited to support the expansion to more physicians and the patients they treat.”

Michael Sjöström, CFA, Co-Founder and Partner of Sectoral Asset Management, said: “We believe Route 92 Medical is positioned for long-term growth with robust manufacturing capacity, a clearly defined market, and a well-differentiated product portfolio. Our investment aims to accelerate its commercial growth, helping the company reach many more hospitals and patients.”

Route 92 Medical’s neurovascular portfolio includes the HiPoint® Reperfusion System, featuring the Monopoint® approach, the first “super-bore” aspiration catheter with a mono-axial procedural approach and a 0.088-inch inner diameter FDA-cleared for the treatment of large vessel occlusions, the cause of many acute ischemic strokes. It joins a suite of purpose-built stroke treatment solutions including the HiPoint 70 Reperfusion System, FreeClimb® 70 Reperfusion System, FreeClimb 54 Reperfusion System, and the FreeClimb 88 Access System. 

This news follows the completion of the company’s SUMMIT MAX clinical trial (NCT05018650), a 250-patient, multicenter, prospective, randomized, and controlled endovascular stroke thrombectomy trial evaluating the safety and efficacy of the HiPoint Reperfusion System featuring the Monopoint approach. Data from the trial demonstrated favorable safety performance and the highest first pass effect ever reported in a randomized, controlled endovascular stroke thrombectomy study. The investigational device exemption (IDE) trial results were submitted to the FDA and, in May 2025, the HiPoint Reperfusion System received thrombectomy marketing clearance from the FDA. Accordingly, Route 92 Medical is the first neurovascular intervention company to receive clearance for direct aspiration of a stroke-causing thrombus with a super-bore 0.088-inch catheter in the neurovasculature. The company’s products are designed to work harmoniously as complete systems to improve the efficiency of endovascular thrombectomy procedures, enabling clinicians to quickly restore blood flow to a patient’s brain following acute ischemic stroke, the most common type of stroke affecting patients today.

About Route 92 Medical, Inc.

Route 92 Medical is on a mission to improve outcomes for patients undergoing neurovascular intervention through cutting-edge engineering and innovative product design. Founded by physicians, the company collaborates with leading neurovascular clinicians to solve the biggest challenges in neurointervention and deliver meaningful, differentiated solutions that promote clinical success. For more information, visit www.r92m.com or follow the company on LinkedIn.

About Novo Holdings A/S

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novonesis and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Planetary Health Investments and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2025, Novo Holdings had total assets of USD 109 billion.